Log In
Print
BCIQ
Print
Print this Print this
 

LixiLan, Lixisenatide/ZP10+Lantus

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionCombination of Lyxumia lixisenatide/ZP10 and Lantus insulin glargine
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today